Poster Abstract Session:
258. Tuberculosis: Epidemiology and Management
Saturday, October 7, 2017: 12:30 PM-2:00 PM
Room: Poster Hall CD

Abdominal tuberculosis in children: experience in a tertiary hospital in Mexico City.
  • Abdominal TB IDweek.pdf (2.2 MB)
  • Latent Tuberculosis Infection in a Cohort of Refugee Patients Resettling in New England
    Amir Mohareb, MD; Bryan Brown, MD; Felona Gunawan, MD; Rupak Datta, MD PhD; Aniyizhai Annamalai, MD; Lydia Barakat, MD
    Risk factors of ethambutol optic neuropathy among patients with tuberculosis and NTM infection
    Sachi Matsubayashi, MD; Eriko Morino, M.D; Yoshie Tsujimoto, MD; Naoko Nagano, MD; Tamaki Kakuwa, MD; Keita Sakamoto, MD; Satoru Ishii, MD; Manabu Suzuki, MD; Jin Takasaki, MD; Go Naka, MD; Motoyasu Iikura, MD; Shinyu Izumi, MD; Yuichiro Takeda, MD; Haruhito Sugiyama, M.D Ph.D
    Detecting TB Cases among Household Contacts of Patients with Pulmonary TB through Active Contact Tracing in the Arsi Zone, Ethiopia.
    Tafese Beyene Tufa, MSc; Tamara Nordmann, MD; Matthias Bosselmann, MD; Andreas Schönfeld, MD; André Fuchs, MD; Torsten Feldt, MD; Dieter Häussinger, MD
    A Cross-Sectional Survey to Measure the Prevalence of Chronic Pulmonary Aspergillosis (CPA) Complicating Pulmonary Tuberculosis in Northern Uganda
    Iain Page, MBChB, MRCP (ID), DTM&H, DipHIV, PhD; Sharath Hosmane, MBChB, FRCR; Nathan Onyachi, MBChB, FRCS; Cyprian Opira, MBChB, FRCR; John Opwonya, BSc; Malcolm Richardson, PhD, FRCPath; Richard Sawyer, MBChB, FRCR; Anna Sharman, MBChB, FRCR; David Denning, MD FRCP FIDSA
    Comparison of Pulmonary Tuberculosis Treatment Efficacy Whit Moxifloxacin for 4 Months Vs. Standard Treatment of Pulmonary Tuberculosis. Intention-to-Treat Analysis (ITT)
    Maria Fernanda Ramirez Amado, medical student; Gerardo Amaya Tapia, MD, PhD; Elizabeth Lopez Villalobos, medical student; Tizoc Vejar-Aguirre, MD; Juan Carlos Villanueva-Arias, MD; Guadalupe Aguirre-Avalos, MD, PhD
    Identification and Characterization of Mycobacterium tuberculosis (Mtb) Effector Proteins
    Sujittra Chaisavaneeyakorn, MD, PhD; Chelsea E. Stamm, B.S.; Michael U. Shiloh, MD, PhD
     Frequency of symptoms and treatment discontinuation during programmatic use of the 12-dose Isoniazid-Rifapentine Regimen for Treatment of Latent Tuberculosis Infection
    Shu-Hua Wang, MD, MPH, PharmD; Christine Ho, MD, MPH; Nwabunie Nwana, MPH; Ruth Moro, MD, MPH; Sapna Morris, MD, MBA; Mark Lobato, MD, MPH; Amy Sandul, CIP, MPH, DHSc; John A. Jereb, MD, FAAP; Mike Holcombe, MPPA, CPM; Lynn Sosa, MD; Vernard Green, MSPH; Sundari Mase, MD, MPH; Brock Stewart, PhD; Terence Chorba, MD, DSc, MPH, MPA, FACP, FIDSA; Risa Webb, MD, DTMH, FIDSA
    Prevalence and Reactivation of Latent Tuberculosis Infection among Foreign-born Subpopulations, United States, 2011–2012
    Rachel Yelk Woodruff, MPH; Andrew Hill, PhD; Suzanne Marks, MPH, MA; Thomas Navin, MD; Roque Miramontes, PA-C, MPH

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.